Barclays PLC Has $10.57 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Barclays PLC lifted its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 192.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 528,629 shares of the biotechnology company’s stock after purchasing an additional 347,692 shares during the quarter. Barclays PLC’s holdings in ADMA Biologics were worth $10,567,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund raised its position in ADMA Biologics by 13.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after purchasing an additional 80,400 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares during the period. Citigroup Inc. raised its holdings in ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after buying an additional 277,138 shares during the last quarter. Seven Eight Capital LP acquired a new stake in ADMA Biologics during the 2nd quarter worth approximately $1,992,000. Finally, Principal Financial Group Inc. grew its holdings in ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after acquiring an additional 1,059,394 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ADMA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright raised their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James upped their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $18.98 on Tuesday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $4.49 billion, a PE ratio of 67.57 and a beta of 0.70. The firm has a fifty day simple moving average of $19.02 and a 200 day simple moving average of $16.10. ADMA Biologics, Inc. has a twelve month low of $4.06 and a twelve month high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same period in the previous year, the business earned $0.01 EPS. On average, sell-side analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.